文献速递心脑血管急症

从时间到结局:急性缺血性卒中溶栓时间与功能结局

From clock to outcomes: Time to thrombolytics and functional outcomes in acute ischemic stroke.
PubMed 文献 · Am J Emerg Med · 2025-06-23
一句话结论回顾性队列显示急性缺血性卒中患者到院后<45分钟与≥45分钟给予阿替普酶,出院时改良Rankin评分≥2无差异(67.5% vs 70.7%)。

该回顾性队列研究纳入2018年12月至2022年10月期间179例确诊急性缺血性卒中并接受阿替普酶治疗的成人患者,比较到院后早期(<45分钟)与延迟(≥45分钟)给药的功能结局。主要终点出院时改良Rankin评分≥2在早期组与延迟组无差异(67.5% vs 70.7%)。任何颅内出血在早期组更常见(20.0% vs 11.1%)。患者同意和神经影像结果是临床医生确定溶栓资格时面临的常见障碍。作者认为溶栓最佳给药时间仍存在不确定性,并为未来研究评估长期功能结局和患者特异性障碍提供了框架。

要点

  • 主要终点出院时改良Rankin评分≥2:早期组67.5% vs 延迟组70.7%,两组无差异。
  • 任何颅内出血发生率早期组20.0% vs 延迟组11.1%,早期组更常见。
  • 患者同意和神经影像结果是确定溶栓资格时临床医生面临的常见障碍。
  • 作者认为溶栓最佳给药时间仍存在不确定性,需未来研究进一步评估长期功能结局和患者特异性障碍。

适用人群与场景

  • 179例成人急性缺血性卒中患者,于2018年12月至2022年10月期间接受阿替普酶治疗。

诊断标准与关键阈值

  • 急性缺血性卒中 eligible 患者在症状发作4.5小时内给予溶栓药物。
  • 主要终点出院时不良功能状态定义为改良Rankin评分≥2。

研究设计与关键结果

  • 研究类型为回顾性队列研究,样本量179例成人患者,人群为急性缺血性卒中接受阿替普酶治疗者。
  • 主要终点出院时改良Rankin评分≥2:早期给药组(<45分钟)67.5% vs 延迟给药组(≥45分钟)70.7%,两组无差异。
  • 任何颅内出血发生率:早期给药组20.0% vs 延迟给药组11.1%,早期组更常见。
  • 中位年龄66岁(范围58.5-77.0岁),男性占49.7%。
  • 患者同意和神经影像结果是临床医生确定溶栓治疗资格时面临的常见障碍。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为溶栓最佳给药时间仍存在不确定性,并为未来研究进一步评估长期功能结局和患者特异性障碍提供了框架。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Thrombolytics are indicated in acute ischemic stroke in eligible patients if administered within 4.5 h of symptom onset. Literature has demonstrated that shorter door-to-needle times improve all-cause mortality and readmission rates, however, it does not report the impact on quality of life. The purpose of this study is to evaluate functional outcomes when alteplase is administered early (< 45 min) versus delayed (≥ 45 min) from time of hospital arrival as well as barriers to meeting goal door-to-needle time.

METHODS: This retrospective, cohort study captured 179 adult patients who received alteplase following diagnosis of acute ischemic stroke between December 2018 and October 2022. The primary endpoint was poor functional status upon hospital discharge, defined as a modified Rankin Score ≥ 2. Secondary endpoints included reasons for alteplase delay and incidence of intracranial hemorrhage.

RESULTS: The median age was 66 [58.5-77.0] years and 49.7 % of the study population was male. For the primary outcome of modified Rankin Score ≥ 2 at discharge, there was no difference between the early and delayed administration groups (67.5 % vs 70.7 %). The incidence of any intracranial hemorrhage was more common in the early administration group (20.0 % vs 11.1 %) In addition, patient consent and neuroimaging results were common barriers clinicians may face when determining eligibility for thrombolytic therapy.

CONCLUSIONS: Our study highlights that optimal administration times of thrombolytics remain an area of uncertainty and provides a framework for future studies to further assess long-term functional outcomes and patient-specific barriers to thrombolytic administration.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. McInerney A, McDowell M, Glowacki N, et al. From clock to outcomes: Time to thrombolytics and functional outcomes in acute ischemic stroke. Am J Emerg Med. 2025. PMID: 40578177. doi:10.1016/j.ajem.2025.06.047

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。